Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9110821 | 0.78 | KDM4E (0.54) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL20008835 | 0.77 | KDM4E (0.53) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL12859249 | 0.77 | KDM4E (0.49) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL14076589 | 0.75 | SMN1; SMN2 (0.55) | KDM4EALDH1A1HTTMAPTSMN1; SMN2 | |
| SCHEMBL9909932 | 0.74 | LMNA (0.53) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL354153 | 0.74 | KDM4E (0.66) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL1963980 | 0.74 | KMT2A (0.49) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL29973132 | 0.74 | MAPT (0.45) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL584903 | 0.74 | MAPT (0.45) | LMNAKDM4EPOLBALDH1A1MEN1 | |
| SCHEMBL2644945 | 0.74 | MAPT (0.48) | LMNAKDM4EPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2015-10-15 | — | — | US | disclosed |
| WO-2014078813-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150291598-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | CYP11B2, CYP11B1, SLC10A1 | LMNA 945/4885KDM4E 3176/4885POLB 3901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.